AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
Log in

NASDAQ:CERCCerecor Stock Price, Forecast & News

$2.43
+0.02 (+0.83 %)
(As of 05/27/2020 12:00 PM ET)
Add
Compare
Today's Range
$2.38
Now: $2.43
$2.54
50-Day Range
$2.15
MA: $2.45
$2.85
52-Week Range
$1.52
Now: $2.43
$6.19
Volume4,837 shs
Average Volume181,269 shs
Market Capitalization$144.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.77
Cerecor Inc., a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device. The company is developing CERC-301, an orphan neurological indication for controlling neurologic adaptation; CERC-406 for the treatment of Parkinson's disease; CERC-425, an orally active small molecule; CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy; and CERC-913, a protide nucleotide for the treatment of mitochondrial disorder. It also developing preclinical therapies CERC-801, CERC-802, and CERC-803 for the treatment of inherited metabolic disorders. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CERC
CUSIPN/A
Phone410-522-8707

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.75 million
Book Value$0.43 per share

Profitability

Net Income$-16,070,000.00

Miscellaneous

Employees64
Market Cap$144.85 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive CERC News and Ratings via Email

Sign-up to receive the latest news and ratings for CERC and its competitors with MarketBeat's FREE daily newsletter.

Cerecor (NASDAQ:CERC) Frequently Asked Questions

How has Cerecor's stock been impacted by COVID-19 (Coronavirus)?

Cerecor's stock was trading at $2.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CERC shares have increased by 0.8% and is now trading at $2.43. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cerecor?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerecor in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cerecor.

When is Cerecor's next earnings date?

Cerecor is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cerecor.

How were Cerecor's earnings last quarter?

Cerecor Inc (NASDAQ:CERC) released its earnings results on Wednesday, March, 11th. The company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.07 by $0.04. View Cerecor's earnings history.

What price target have analysts set for CERC?

4 analysts have issued 1 year target prices for Cerecor's stock. Their forecasts range from $10.00 to $12.00. On average, they anticipate Cerecor's share price to reach $10.50 in the next year. This suggests a possible upside of 332.1% from the stock's current price. View analysts' price targets for Cerecor.

What are Wall Street analysts saying about Cerecor stock?

Here are some recent quotes from research analysts about Cerecor stock:
  • 1. Maxim Group analysts commented, "Cerecor reported positive Parkinson’s disease (PD)- related neurogenic orthostatic hypotension (nOH). Key takeaways from the data include demonstration of a rapid and sustained improvement in systolic blood pressure upon standing particularly in the highest dose group (20mg); >7mmHg with max improvement of 29.1mmHg." (7/2/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "We reiterate our Buy rating and $8 PT. Full data set is consistent with interim data." (7/2/2019)
  • 3. HC Wainwright analysts commented, "We value Cerecor based on a discounted cash flow (DCF) approach that ascribes a total value of $530M to the company’s marketed product portfolio, neurology-focused assets and ultra-rare early-stage product candidate pipeline." (5/28/2019)

Has Cerecor been receiving favorable news coverage?

News articles about CERC stock have trended somewhat positive on Wednesday, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cerecor earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutCerecor.

Who are some of Cerecor's key competitors?

What other stocks do shareholders of Cerecor own?

Who are Cerecor's key executives?

Cerecor's management team includes the following people:
  • Ms. Mariam E. Morris, Consultant (Age 51)
  • Dr. Simon C. Pedder Ph.D., Exec. Chairman (Age 58)
  • Mr. Joseph M. Miller CPA, Chief Financial Officer (Age 45)
  • Dr. Solomon H. Snyder, Founder and Chairman of Scientific Advisory Board (Age 80)
  • Dr. Barbara S. Slusher, Founder and Member of Scientific Advisory Board (Age 54)

What is Cerecor's stock symbol?

Cerecor trades on the NASDAQ under the ticker symbol "CERC."

Who are Cerecor's major shareholders?

Cerecor's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.14%), Ikarian Capital LLC (0.95%), State Street Corp (0.67%), Geode Capital Management LLC (0.45%), Nuveen Asset Management LLC (0.12%) and Invesco Ltd. (0.10%). Company insiders that own Cerecor stock include Armistice Capital Master Fund, Armistice Capital, Llc, Cerecor Inc, James Archie Harrell Jr, Joseph M Miller, Matthew V Phillips, Pericles Calias and Simon Pedder. View institutional ownership trends for Cerecor.

Which major investors are selling Cerecor stock?

CERC stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Spark Investment Management LLC, JPMorgan Chase & Co., and UBS Group AG. View insider buying and selling activity for Cerecor.

Which major investors are buying Cerecor stock?

CERC stock was bought by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, Ikarian Capital LLC, Geode Capital Management LLC, Los Angeles Capital Management & Equity Research Inc., Nuveen Asset Management LLC, Invesco Ltd., and State Street Corp. Company insiders that have bought Cerecor stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc, James Archie Harrell Jr, Joseph M Miller, Matthew V Phillips, Pericles Calias, and Simon Pedder. View insider buying and selling activity for Cerecor.

How do I buy shares of Cerecor?

Shares of CERC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cerecor's stock price today?

One share of CERC stock can currently be purchased for approximately $2.43.

How big of a company is Cerecor?

Cerecor has a market capitalization of $144.85 million and generates $6.75 million in revenue each year. The company earns $-16,070,000.00 in net income (profit) each year or ($0.30) on an earnings per share basis. Cerecor employs 64 workers across the globe.

What is Cerecor's official website?

The official website for Cerecor is www.cerecor.com.

How can I contact Cerecor?

Cerecor's mailing address is 540 Gaither Road Suite 400, Rockville MD, 20850. The company can be reached via phone at 410-522-8707 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.